CO5550453A2 - Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) - Google Patents
Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)Info
- Publication number
- CO5550453A2 CO5550453A2 CO05024820A CO05024820A CO5550453A2 CO 5550453 A2 CO5550453 A2 CO 5550453A2 CO 05024820 A CO05024820 A CO 05024820A CO 05024820 A CO05024820 A CO 05024820A CO 5550453 A2 CO5550453 A2 CO 5550453A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heteroaryl
- amino
- aryl
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto de fórmula (la): o una sal, profármaco, tautómero, hidrato y solvato farmacéuticamente aceptable del mismo, en el queR1 es un anillo saturado, insaturado o aromático mono-, bi-, o policíciclo C3-C20 que contiene opcionalmente al menos un heteroátomo seleccionado del grupo constituido por N, O y S, en el que R1 además puede estar opcionalmente sustituido independientemente al menos con un resto seleccionado independientemente del grupo constituido por: carbonilo, halo, haloalquilo C1-C6, perhaloalquilo C1-C6, perhaloalcoxi C1-C6, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, hidroxi, oxo, mercapto, alquiltio C1-C6, alcoxi C1-C6, arilo C5-C10, o heteroarilo C5-C10, ariloxi C5-C10, o heteroariloxi C5-C10, (ar C5-C10)alquilo C1-C6 o (heteroar C5-C10)alquilo C1-C6, (ar C5-C10)alcoxi C1-C6 o (heteroar C5-C10)a]coxi C1-C6, HO-(C=O)-, éster, amido, éter, amino, aminoalquilo C1-C6, (alquil C1-C6)aminoalquilo C1-C6, di(alquil C1-C6)aminoalquilo C1-C6, (heterociclil C5-C10)alquil C1-C6, (alquil C1-C6) y di(alquil C1-C6)amino, ciano, nitro, carbamoilo, (alquil C1-C6)carbonilo, (alcoxi C1-C6)carbonilo, (alquil C1-C6)aminocarbonilo, di(alquil C1-C6)aminocarbonilo, (aril C5-C10)carbonilo, (aril C5-C10)oxicarbonilo, (alquil C1-C6)sulfonilo, y (aril C5-C10)sulfonilo;cada R3 se selecciona independientemente del grupo constituido por: hidrógeno, halo, haloalquilo C1-C6, alquilo C1-C6, alquenilo C2-C6, alquinilo C2-C6, perhaloalquilo C1-C6, fenilo, heteroarilo C5-C10, heterociclo C5-C10, cicloalquilo C3-C10, hidroxi, alcoxi C1-C6, perhaloalcoxi C1-C6, fenoxi, (heteroaril C5-C10)-O-, (heterociclo C5-C10)-O-, (cicloalquil C3-C10)-O-, (alquil C1-C6)-S-, (a]quil C1-C6)-SO2-, (alquil C1-C6)-NH-SO2-, -O2N, -NC, amino, -Ph(CH2)1-6HN, -(alquil C1-C6)-HN, (alquil C1-C6)amino, [(alquil C1-C6)]2-amino, (alquil C1-C6)-SO2-NH-, amino-(C=O), -amino-O2S-, (alquil C1-C6)-(C=O)-NH-, (alquil C1-C6)-(C=O)-[(alquil C1-C6)-N]-, fenil-(C=O)-NH-, fenil-(C=O)-[(alquil C1-C6)-N]-, (alquil C1-C6)-(C=O)-, fenil-(C=O)-, (heteroaril C5-C10)-(C=O)-, (heterociclo C5-C10)-(C=O)-, (cicloalquil C3-C10)-(C=O)-, HO-(C=O)-, (alquil C1-C6)-O-(C=O)-, H2N-(C=O)-, (alquil C1-C6)-NH-(C=O)-, [(alquil C1-C6)]2-N-(C=O)-, fenil-NH-(C=O)-, fenil-[(alquil C1-C6)-N]-(C=O)-, (heteroaril C5-C10)-NH-(C=O)-, (heterociclo C5-C10)-NH-(C=O)-, ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41189402P | 2002-09-18 | 2002-09-18 | |
| US48452203P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5550453A2 true CO5550453A2 (es) | 2005-08-31 |
Family
ID=32033577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05024820A CO5550453A2 (es) | 2002-09-18 | 2005-03-17 | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7153872B2 (es) |
| EP (1) | EP1542990B1 (es) |
| JP (1) | JP4547271B2 (es) |
| KR (1) | KR20050057392A (es) |
| CN (1) | CN1681805A (es) |
| AP (1) | AP2005003264A0 (es) |
| AR (1) | AR041274A1 (es) |
| AT (1) | ATE433968T1 (es) |
| AU (1) | AU2003263404A1 (es) |
| BR (1) | BR0314372A (es) |
| CA (1) | CA2498047C (es) |
| CO (1) | CO5550453A2 (es) |
| DE (1) | DE60328028D1 (es) |
| EA (1) | EA200500378A1 (es) |
| EC (1) | ECSP055680A (es) |
| ES (1) | ES2325687T3 (es) |
| HR (1) | HRP20050252A2 (es) |
| IS (1) | IS7712A (es) |
| MA (1) | MA27441A1 (es) |
| MX (1) | MXPA05002981A (es) |
| NO (1) | NO20051008L (es) |
| OA (1) | OA12928A (es) |
| PA (1) | PA8583301A1 (es) |
| PE (1) | PE20050072A1 (es) |
| PL (1) | PL375980A1 (es) |
| TW (1) | TW200404793A (es) |
| UY (1) | UY27982A1 (es) |
| WO (1) | WO2004026859A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| MXPA05002981A (es) * | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf). |
| JP4518956B2 (ja) | 2002-09-18 | 2010-08-04 | ファイザー・プロダクツ・インク | トランスフォーミング成長因子（ｔｇｆ）阻害剤としての新規トリアゾールおよびオキサゾール化合物 |
| AP2005003263A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Pyrazole derivatives as transforming growth factor(TGF) inhibitors. |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| US20080319012A1 (en) * | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| RU2427572C2 (ru) * | 2004-06-18 | 2011-08-27 | Чирон Корпорейшн | N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака |
| CA2578630A1 (en) * | 2004-08-31 | 2006-03-09 | Wen-Cherng Lee | Pyrimidinylimidazoles as tgf-beta inhibitors |
| EP1798229A4 (en) * | 2004-09-07 | 2009-07-29 | Sankyo Co | SUBSTITUTED BIPHENYL DERIVATIVE |
| PE20070427A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas |
| KR20080082618A (ko) * | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Ａｌｋ5 조절제를 사용한 안압의 조절 |
| CN1990473B (zh) * | 2005-12-30 | 2013-07-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 三取代1h-咪唑类化合物、其制备方法、药物组合物及其制药用途 |
| WO2008094556A2 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| JP2010529031A (ja) * | 2007-05-29 | 2010-08-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体 |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8129394B2 (en) * | 2008-03-21 | 2012-03-06 | Novartis Ag | Heteroaryl-substituted imidazole compounds and uses thereof |
| WO2009126861A2 (en) | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as dgat1 inhibitors |
| US8324241B2 (en) | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| WO2009155388A1 (en) | 2008-06-20 | 2009-12-23 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors |
| JO2892B1 (en) | 2009-06-26 | 2015-09-15 | نوفارتيس ايه جي | CYP inhibitors 17 |
| DE102009043260A1 (de) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| DE102010049595A1 (de) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| PT3089971T (pt) | 2014-01-01 | 2020-09-03 | Medivation Tech Llc | Compostos e métodos de utilização |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| WO2018132279A1 (en) * | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| CN113195467A (zh) | 2018-12-11 | 2021-07-30 | 施万生物制药研发Ip有限责任公司 | 适用作alk5抑制剂的萘啶和喹啉衍生物 |
| JP2023502662A (ja) | 2019-11-22 | 2023-01-25 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン |
| KR102539660B1 (ko) | 2020-08-20 | 2023-06-02 | 가천대학교 산학협력단 | 베타-폴리비닐리덴 플루오라이드 코팅층이 형성된 아연 음극 및 상기 음극을 포함하는 수계 아연 이온 전지 |
| KR20220031386A (ko) | 2020-09-04 | 2022-03-11 | 고려대학교 세종산학협력단 | 전기화학적 및 광전기화학적 수소 생산용 황화니켈 나노결정 촉매 및 이의 제조방법 |
| US20230089180A1 (en) * | 2021-08-13 | 2023-03-23 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds and use thereof |
| CN115466260B (zh) * | 2022-09-06 | 2023-10-13 | 延边大学 | 含氨基酸结构的咪唑和噻唑类衍生物及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3707475A (en) | 1970-11-16 | 1972-12-26 | Pfizer | Antiinflammatory imidazoles |
| IL83467A0 (en) * | 1986-08-15 | 1988-01-31 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same |
| US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| IL132736A0 (en) | 1997-05-22 | 2001-03-19 | Searle & Co | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
| EP1169317B1 (en) * | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazoles |
| CO5271680A1 (es) * | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| AU2002225730A1 (en) | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| ES2237671T3 (es) | 2001-02-02 | 2005-08-01 | Smithkline Beecham Corporation | Derivados de pirazol contra la sobreexpresion de tgf. |
| GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| EP1363904A1 (en) | 2001-02-02 | 2003-11-26 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| JP2004526727A (ja) * | 2001-03-09 | 2004-09-02 | ファイザー・プロダクツ・インク | ベンゾイミダゾール抗炎症化合物 |
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| AR040726A1 (es) | 2002-07-31 | 2005-04-20 | Smithkline Beecham Corp | Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento |
| AU2003263431A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
| JP4518956B2 (ja) | 2002-09-18 | 2010-08-04 | ファイザー・プロダクツ・インク | トランスフォーミング成長因子（ｔｇｆ）阻害剤としての新規トリアゾールおよびオキサゾール化合物 |
| AP2005003260A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel triazole compounds as transforming growth factor (TGF) inhibitors. |
| MXPA05002981A (es) | 2002-09-18 | 2005-06-22 | Pfizer Prod Inc | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf). |
| AP2005003263A0 (en) | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Pyrazole derivatives as transforming growth factor(TGF) inhibitors. |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
-
2003
- 2003-09-08 MX MXPA05002981A patent/MXPA05002981A/es active IP Right Grant
- 2003-09-08 BR BR0314372-4A patent/BR0314372A/pt not_active IP Right Cessation
- 2003-09-08 PL PL03375980A patent/PL375980A1/xx not_active Application Discontinuation
- 2003-09-08 AU AU2003263404A patent/AU2003263404A1/en not_active Abandoned
- 2003-09-08 WO PCT/IB2003/003833 patent/WO2004026859A1/en active Application Filing
- 2003-09-08 CN CNA038221608A patent/CN1681805A/zh active Pending
- 2003-09-08 ES ES03797429T patent/ES2325687T3/es not_active Expired - Lifetime
- 2003-09-08 AP AP2005003264A patent/AP2005003264A0/xx unknown
- 2003-09-08 EA EA200500378A patent/EA200500378A1/ru unknown
- 2003-09-08 EP EP03797429A patent/EP1542990B1/en not_active Expired - Lifetime
- 2003-09-08 KR KR1020057004570A patent/KR20050057392A/ko not_active Application Discontinuation
- 2003-09-08 OA OA1200500077A patent/OA12928A/en unknown
- 2003-09-08 AT AT03797429T patent/ATE433968T1/de not_active IP Right Cessation
- 2003-09-08 JP JP2004568901A patent/JP4547271B2/ja not_active Expired - Fee Related
- 2003-09-08 DE DE60328028T patent/DE60328028D1/de not_active Expired - Lifetime
- 2003-09-08 CA CA002498047A patent/CA2498047C/en not_active Expired - Fee Related
- 2003-09-16 PE PE2003000942A patent/PE20050072A1/es not_active Application Discontinuation
- 2003-09-16 UY UY27982A patent/UY27982A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103358A patent/AR041274A1/es unknown
- 2003-09-17 TW TW092125609A patent/TW200404793A/zh unknown
- 2003-09-17 PA PA20038583301A patent/PA8583301A1/es unknown
- 2003-09-17 US US10/666,192 patent/US7153872B2/en not_active Expired - Fee Related
-
2005
- 2005-02-24 IS IS7712A patent/IS7712A/is unknown
- 2005-02-24 NO NO20051008A patent/NO20051008L/no unknown
- 2005-03-17 CO CO05024820A patent/CO5550453A2/es not_active Application Discontinuation
- 2005-03-17 EC EC2005005680A patent/ECSP055680A/es unknown
- 2005-03-17 HR HR20050252A patent/HRP20050252A2/hr not_active Application Discontinuation
- 2005-03-18 MA MA28155A patent/MA27441A1/fr unknown
-
2006
- 2006-11-10 US US11/558,624 patent/US7635702B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1681805A (zh) | 2005-10-12 |
| ATE433968T1 (de) | 2009-07-15 |
| DE60328028D1 (de) | 2009-07-30 |
| NO20051008L (no) | 2005-06-07 |
| ECSP055680A (es) | 2005-05-30 |
| AP2005003264A0 (en) | 2005-03-31 |
| WO2004026859A1 (en) | 2004-04-01 |
| CA2498047A1 (en) | 2004-04-01 |
| US20070088037A1 (en) | 2007-04-19 |
| US7635702B2 (en) | 2009-12-22 |
| PL375980A1 (en) | 2005-12-12 |
| MA27441A1 (fr) | 2005-07-01 |
| US7153872B2 (en) | 2006-12-26 |
| PA8583301A1 (es) | 2004-09-16 |
| IS7712A (is) | 2005-02-24 |
| UY27982A1 (es) | 2004-04-30 |
| JP4547271B2 (ja) | 2010-09-22 |
| CA2498047C (en) | 2009-05-19 |
| EA200500378A1 (ru) | 2005-08-25 |
| EP1542990A1 (en) | 2005-06-22 |
| AU2003263404A1 (en) | 2004-04-08 |
| MXPA05002981A (es) | 2005-06-22 |
| ES2325687T3 (es) | 2009-09-14 |
| AR041274A1 (es) | 2005-05-11 |
| HRP20050252A2 (en) | 2005-10-31 |
| KR20050057392A (ko) | 2005-06-16 |
| PE20050072A1 (es) | 2005-03-01 |
| US20040106608A1 (en) | 2004-06-03 |
| EP1542990B1 (en) | 2009-06-17 |
| TW200404793A (en) | 2004-04-01 |
| BR0314372A (pt) | 2005-07-19 |
| JP2006502237A (ja) | 2006-01-19 |
| OA12928A (en) | 2006-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5550453A2 (es) | Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf) | |
| CO5550456A2 (es) | Nuevos compuestos de piraol como inhibidores del factor de crecimiento transformante (tgf) | |
| CO5540390A2 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
| CO5550473A2 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformadors (tgf) | |
| CO5550458A2 (es) | Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf) | |
| ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| PE20231938A1 (es) | Inhibidores de cdk y metodos de uso de estos | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| AR043449A1 (es) | Compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf) | |
| ECSP034551A (es) | Secretagogos de hormona del crecimiento | |
| PE20020707A1 (es) | Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c | |
| DOP2002000334A (es) | Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| MY140039A (en) | Pyrido-(2,1-a)-isoquinoline derivatives as dpp-iv inhibitors | |
| PE20040836A1 (es) | Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc) | |
| CO4960641A1 (es) | Derivados de piperidina 1,4-disustituida conteniendo fluor | |
| PE20010482A1 (es) | Derivados de 3-ureido-pirazol y procedimiento para su preparacion | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| GB1600461A (en) | Sulphur-containing peptides | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| MA32456B1 (fr) | Dérivé hétérocyclique contenant du soufre ayant une activité inhibant la b-sécrétase | |
| ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
| CO5690599A2 (es) | Derivados de 3-(4-aminofenil) tienopirimid-4-ona como antagonistas mch r1 para el tratamiento de obesidad, diabetes, depresion y ansiedad | |
| AR035943A1 (es) | Derivados de la quinolil propil piperidina, su preparacion y las composiciones farmaceuticas que los contienen | |
| ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |